Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria

Pathogens and Global Health

Volumn 106, Issue 1, 2012, Pages 46-54

  Onoka, C A ^a   Uzochukwu, B S ^a   Onwujekwe, O E ^a   Chukwuka, C ^a   Ilozumba, J ^b   Onyedum, C ^a   Nwobi, E A ^a   Onwasigwe, C ^a  

^a UNIVERSITY OF NIGERIA   (Nigeria)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; HIV; Loss to follow up; Nigeria; Retention

Indexed keywords

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD; MORTALITY; NIGERIA; PATIENT INFORMATION; PATIENT PARTICIPATION; PRIVATE HOSPITAL; PUBLIC HEALTH SERVICE; PUBLIC HOSPITAL; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NIGERIA; TREATMENT OUTCOME;

EID: 84864042686     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773211Y.0000000018     Document Type: Article

References (32)

1. UNAIDS. Report on the global HIV/AIDS epidemic 2008. Joint United Nations Programme on HIV/AIDS, 2008, Geneva, Switzerland.
2. UNAIDS. Towards universal access: scaling up priority HIV/ AIDS interventions in the health sector. Progress report 2008. UNAIDS, Geneva, Switzerland.
3. UNAIDS. Global HIV/AIDS response: epidemic update and health sector progress towards universal access. Progress report 2011. Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland.
4. UNAIDS. UNAIDS data tables 2011. Joint United Nations Programme on HIV/AIDS (UNAIDS), 2011, Geneva, Switzerland.
5. Calmy A, Klement E, Teck R, Berman D, Pecoul B, Ferradini L. Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up. AIDS. 2004;18:2353-60.
6. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter TF, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005; 40:336-43.
7. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, Yiannoutsos CT, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS. 2006;20:41-8.
8. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4:e298.
9. Yu JK, Chen SC, Wang KY, Chang CS, Makombe SD, Schouten EJ, et al. True outcomes for patients on antiretroviral therapy who are 'lost to follow-up' in Malawi. Bulletin of the World Health Organization. 2007;85:550-554.
10. MOH Malawi. ARV therapy in Malawi-up to 31st March 2006. Quarterly report. HIV Unit, Ministry of Health Malawi, 2006, Lilongwe, Malawi.
11. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-24.
12. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-42.
13. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006;20:1163-9.
14. UNAIDS. Towards universal access: scaling up priority HIV/ AIDS interventions in the health sector. Progress report 2009. Geneva, Switzerland, UNAIDS.
15. Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S, et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative-Uganda. AIDS. 2003;17(Suppl 3), S39-S48.
16. Poppa A, Davidson O, Deutsch J, Godfrey D, Fisher M, Head S, et al. British HIV Association (BHIVA)/British Association for Sexual Health and HIV (BASHH) guidelines on provision of adherence support to individuals receiving antiretroviral therapy (2003). HIV Med. 5(Suppl 2), 46-60.
17. Hanson K, Hicks C. New antiretroviral drugs. Curr HIV/AIDS Rep. 2006;3:93-101.
18. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis. 2005;5:115-9.
19. Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O'Brien TF, et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis. 2005;5:481-93.
20. National Bureau of Statistics. Federal Republic of Nigeria: 2006 population census. Abuja, Nigeria, Federal Government of Nigeria, 2006, [cited 07/07/09]. Available at: www.nigerianstat. gov.ng.
21. Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noel JM, M'Bangue M, et al. Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis. 2005;41:108-11.
22. Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr. 2007;45:304-10.
23. Kabugo C, Bahendeka S, Mwebaze R, Malamba S, Katuntu D, Downing R, et al. Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4z cell count responses. J Acquir Immune Defic Syndr. 2005;38:578-83.
24. Tsague L, Koulla SS, Kenfak A, Kouanfack C, Tejiokem M, Abong T, et al. Determinants of retention in care in an antiretroviral therapy (ART) program in urban Cameroon, 2003-2005. Pan African Med J. 2008;1:2.
25. Taylor-Smith K, Tweya H, Harries A, Schoutene E, Jahn A. Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi. Malawi Med J. 2010;22:49-56.
26. Pacheco AG, Saraceni V, Tuboi SH, Moulton LH, Chaisson RE, Cavalcante SC, et al. Validation of a hierarchical deterministic record-linkage algorithm using data from 2 different cohorts of human immunodeficiency virus-infected persons and mortality databases in Brazil. Am J Edpidemiol. 2008;168:1326-32.
27. Akesode FA. Registration of births and deaths in Lagos, Nigeria. J Tropl Pediatr. 1980;26:150-5.
28. Akande TM, Sekoni OO. A survey of birth and death registration in a semi-urban settlement in middle-belt Nigeria. Eur J Sci Res. 2005;8:56-61.
29. Onwujekwe O, Dike N, Chukwuka C, Uzochukwu B, Onyedum C, Onoka C, et al. Examining catastrophic costs and benefit incidence of subsidized antiretroviral treatment (ART) programme in south-east Nigeria. Health Policy. 2009;90:223-9.
30. World Bank. Averting a human crisis during the global downturn: policy options from the World Bank's human development network. Washington, DC, USA, 2009 [cited June 2009]. Available at: http://www.uniteforchildren. org/files/world_bank.pdf (accessed 12 June 2009).
31. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. Jf Antimicrob Chemother. 2005;55:413-6.
32. Desvarieux M, Landman R, Liautaud B, Girard PM. Antiretroviral therapy in resource-poor countries: illusions and realities. Am J Public Health. 2005;95:1117-22.